OTCMKTS:ZYXI - Zynex Stock Price, Forecast & News

Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."

Zynex Inc. (OTCMKTS:ZYXI) announced its quarterly earnings results on Tuesday, October, 29th. The company reported $0.06 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.00. The company had revenue of $11.82 million for the quarter, compared to analyst estimates of $11.06 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%. View Zynex's Earnings History.

Zynex issued an update on its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $45.3-45.8 million, compared to the consensus revenue estimate of $44.11 million.

2 Wall Street analysts have issued 12-month price objectives for Zynex's shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Zynex's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price. View Analyst Price Targets for Zynex.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynex.

News articles about ZYXI stock have trended extremely positive on Saturday, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zynex earned a media sentiment score of 5.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for Zynex.

Some companies that are related to Zynex include Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), Stereotaxis (STXS), Semler Scientific (SMLR), BioLife Solutions (BLFS), Viewray (VRAY), Soleno Therapeutics (SLNO), Rockwell Medical (RMTI), Fonar (FONR), BioSig Technologies (BSGM), Edap Tms (EDAP), Second Sight Medical Products (EYES) and IRIDEX (IRIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynex investors own include FuelCell Energy (FCEL), Melinta Therapeutics (MLNT), Altria Group (MO), Penumbra (PEN), Aldeyra Therapeutics (ALDX), BioDelivery Sciences International (BDSI), Codexis (CDXS), Catalyst Pharmaceuticals (CPRX), HEXO (HEXO) and Heron Therapeutics (HRTX).

Zynex's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Calamos Advisors LLC (0.77%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard. View Institutional Ownership Trends for Zynex.

ZYXI stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC. Company insiders that have sold Zynex company stock in the last year include Daniel J Moorhead and Thomas Sandgaard. View Insider Buying and Selling for Zynex.

Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZYXI stock can currently be purchased for approximately $10.12.

Zynex has a market capitalization of $331.36 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. View Additional Information About Zynex.

The official website for Zynex is http://www.zynexmed.com/.

Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]